rova-t fall short third-lin sclc triniti
lung cancer sclc result came expect show overal
respons rate orr median durat respons dor month
median overal surviv os month one-year surviv probabl
march market open releas top-lin result
pivot triniti studi rova-t rovalpituzumab tesirin third-lin small cell
base data elect pursu acceler approv
rova-t third-lin sclc triniti data third-lin sclc patient show
larg discrep orr investigator-assess respons independ
review committee-assess respons much lower shown
earlier phase studi includ orr third-lin sclc patient like
investigator-assess much smaller patient cohort orr signific
enough priorit acceler approv note bristol-my squibb
outperform checkmat studi opdivo yervoy second- later-lin
sclc demonstr orr os month mix patient popul
compris second- third-lin sclc patient combin garner
acceler approv comparison triniti data phase rova-t data
checkmat provid exhibit
share pull back intra-day rova-t first product
repres solid tumor oncolog franchis previous guid
peak sale rova-t billion third line sclc compos
sclc also indic bring question valid
disregard rova-t valuat note rova-t undergo evalu
number trial includ on-going phase studi meru taho first-
second-lin sclc respect rova-t synerg agent basket
studi rova-t opdivo /-yervoy on-going might becom fruit howev note
meru taho read beyond rova-t compani seven
agent acquir stemcentrx pipelin clinic evalu plan file around
candid multibillion-dollar stemcentrx acquisit larg extent
stemcentrx acquisit pullback signal us market larg
million estim defeat triniti cast doubt rova-t potenti
return equiti ttm
biopharmaceut compani major busi franchis autoimmun oncolog virolog
area base north chicago illinoi
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
despit pullback maintain outperform rate decreas fair-valu estim share
base follow chang model due partner
market perform decis earli march withdraw zinbryta remov zinbryta model base
pivot triniti studi third-lin later sclc compani decis seek acceler approv
delay rova-t launch second half second half updat averag price-to-earnings multipl
comp group valuat purpos take averag non-gaap ep estim
estim estim compar previou averag
respect multipl chosen percentil compar biotech pharmaceut
multipl given year accord model top- bottom-lin compound-annual-growth-rate respect
beyond humira revenu start declin project top- bottom-lin compound-annual-growth-rate
respect howev note project includ current market product late-stag
pipelin candid believ current earlier-stag asset start contribut growth beyond
result chang model deriv new fair-valu estim
trial ii pivot phase iindic third-lin small cell lung cancer second third-lin small cell lung mg/kg rova-t escal mg/kg rova-t mg/kg opdivoi diseas mg/kg mg/kg yervoyi four mg/kg opdivoi diseas progressionpati number cell current/form smoker express smoker express respons rate irc investig second third overal surviv durat monthsmedian overal monthsmedian monthsseri advers event rate grade photosensit reaction pleural effus compani reportsexhibit inc rova-t efficaci third-lin patient versu checkpoint inhibitor therapi sclccheckmat i/iisecond-lin later small cell lung cancer import disclosur
